CurrentCignaPolicy IP0343

Vuity (pilocarpine 1.25% ophthalmic) drug coverage

This policy governs Cigna coverage determinations for Vuity (pilocarpine 1.25% ophthalmic) for treatment of presbyopia under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyVuity (pilocarpine 1.25% ophthalmic) drug coverage

Policy CodePolicy IP0343

Change TypeNo material change

Effective DateApr 15, 2024

Next Review Date

Key ActionFollow standard Cigna prior authorization processes and submit clinical rationale if requesting coverage for Vuity contrary to policy.

SourceLink

Not medically necessaryCoverage stance for Vuity for presbyopia

FDA-approvedVuity indicated for presbyopia in adults

AnnualPolicy review cadence

Cigna plansApplies to

Coverage Determinations

Not medically necessary for presbyopia

Covered when ALL of the following are met:

Primary coverage rule: Vuity for the treatment of presbyopia is considered NOT medically necessary.

Presbyopia is characterized as a normal age-related change rather than an illness, injury, disease, or its symptoms; therefore treatment is not medically necessary.

Treatment of presbyopia with Vuity is explicitly listed as a condition not covered. Any use of Vuity for the indication of presbyopia is considered not medically necessary under this policy.

The policy rationale states that although Vuity is FDA-approved for presbyopia in adults, coverage is limited to treatments required to diagnose or treat an illness, injury, disease or its symptoms. Presbyopia is described as the irreversible loss of accommodative ability due to aging, a natural age-related change rather than an illness; therefore use of Vuity for presbyopia is considered not medically necessary.

Provider Requirements and Actions

Policy Summary

PayerCigna

PolicyVuity (pilocarpine 1.25% ophthalmic) drug coverage

Policy CodePolicy IP0343

Change TypeNo material change

Effective DateApr 15, 2024

Next Review Date

Key ActionFollow standard Cigna prior authorization processes and submit clinical rationale if requesting coverage for Vuity contrary to policy.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior Authorization

Prior Authorization Required

Prior authorization required per plan. Verify member benefits and authorization requirements prior to initiating therapy.

Prior authorization may be required per the member's plan
Check the member's benefit booklet or contact Cigna Provider Services for authorization status

Denial Risk

Denial for Presbyopia Indication

Requests for Vuity for presbyopia will be denied as not medically necessary. Presbyopia is a normal, age-related loss of accommodation and is listed under Conditions Not Covered for this policy.

Vuity for presbyopia — Not medically necessary

Documentation Required

Documentation and Review Expectations

Documentation and review expectations: Review the member's applicable benefit plan document, any relevant federal or state laws/regulations, and collateral materials (including this Coverage Policy) when making coverage determinations. Include clinical rationale and supporting documentation in the request to facilitate review. Medical directors and reviewers will exercise clinical judgment and consider the specific facts of each request.

Confirm terms of the applicable benefit plan document in effect on date of service
Reference any applicable laws or regulations
Provide clinical documentation and rationale to support medical necessity determinations
Medical directors may use discretion based on the totality of information provided

Note

Nonpharmacologic Alternatives

Nonpharmacologic alternatives should be considered and documented prior to approval of therapy for vision correction when applicable. Alternatives include corrective lenses and surgical options.

Eyeglasses (single vision, bifocal, multifocal as appropriate)
Contact lenses (soft, rigid gas-permeable, aspheric bifocal or multifocal)
Surgical management options (keratorefractive surgery, corneal inlays, intraocular lens implantation such as multifocal, accommodative, or extended depth of focus lenses)

Clinical Background

Presbyopia is an age-related, irreversible decline in the eye’s accommodative ability that commonly begins in the early to mid-40s and progresses with age. The policy describes presbyopia as a natural consequence of aging — "the irreversible loss of the accommodative ability of the eye that occurs due to aging" — and frames it as not resulting from illness, injury, disease or its symptoms.

Key Definitions

Presbyopia — definition of irreversible loss of accommodation

DefinitionThe irreversible loss of the accommodative ability of the eye that occurs due to aging; typically begins in the early to mid‑40s with complete loss of accommodation around ages 50–55.

EtiologyResults from gradual thickening and loss of flexibility of the natural lens; a natural aging process rather than an illness or injury.

Typical presentationGradual onset of blurred near vision; may include squinting, headaches from eye strain, increased light requirement, and need to work from progressively greater distances.

Distinguishing featuresDiffers from refractive errors (astigmatism, myopia, hyperopia) which are related to eyeball shape and genetic/environmental factors.

Vuity (pilocarpine 1.25% ophthalmic) — drug definition and indication

Drug class and formulationPilocarpine 1.25% ophthalmic (brand: Vuity) — a cholinergic muscarinic receptor agonist formulated as topical ophthalmic solution.

IndicationIndicated for the treatment of presbyopia in adults.

Regulatory status referencedDescribed in policy as FDA‑approved for treatment of presbyopia in adults.

Policy relevanceThis medication is the subject of the policy (IP0343) determining coverage for presbyopia treatment; use for presbyopia is addressed directly by the coverage stance.